2014 Financial Results

by

Most contract service providers that publicly report financial results had done so by the end of March 2015. In our March issue of Bio/Pharmaceutical Outsourcing Report, we review the summary results for the key service sectors: API, finished dose form (FDF), clinical research and lab services. The table below provides the details for the companies included in that article.

Notes:

  • Catalent results are for 12 months ended 12/31/2014. Company fiscal year is 6/30.
  • Famar is private, but reported revenues on website.
  • SGS Life Sciences includes clinical CRO revenues, but they are not broken out from lab services.

Related Posts:
The Rich Get Richer
Big Jump in Early Phase Trials
How big is the market for…?

Jim Miller is the founder and president of PharmSource Information Services, Inc. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the industry’s principal resource for serious consumers of information on contract drug development and manufacturing, PharmSource STRATEGIC ADVANTAGE. He is editor and publisher of Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report.

More posts by Jim Miller